Schall Law Firm Investigates CARGO Therapeutics Over Potential Securities Violations

The Schall Law Firm, a well-known national shareholder rights litigation firm, is looking into claims against CARGO Therapeutics, Inc. (“CARGO” or “the Company”) CRGX. The investigation centers on possible violations of the securities laws.

Concerns About Misleading Statements and Clinical Study Discontinuation

This inquiry is focused on whether CARGO made false or misleading statements or failed to disclose critical information to investors. On January 29, 2025, the Company announced in a press release its decision to discontinue the FIRCE-1 clinical study. This Phase 2 study was examining firi-cel for patients suffering from large B-cell lymphoma (LBCL) whose disease had relapsed or did not respond to CD19 CAR T-cell therapy. The Company stated, “Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended patient population.”

Opportunity for Shareholders to Act

Shareholders who have experienced financial losses are encouraged to participate in the investigation by clicking here.

Contact Information for Further Inquiries

Investors can contact Brian Schall at the Schall Law Firm for a free consultation regarding their rights. Reach him at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or call 310-301-3335. More information is available on the firm’s website at www.schallfirm.com, or by email at [email protected].

About Schall Law Firm

The Schall Law Firm represents investors globally, focusing on securities class action lawsuits and shareholder rights litigation.

This announcement may be considered Attorney Advertising in certain jurisdictions based on applicable laws and ethical guidelines.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20250129329540/en/

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

[email protected]

www.schallfirm.com